

4° ΔΙΑΠΑΝΕΠΙΣΤΗΜΙΑΚΟ ΠΡΟΓΡΑΜΜΑ ΕΚΠΑΙΔΕΥΣΗΣ ΣΤΗ ΡΕΥΜΑΤΟΛΟΓΙΑ 2022-24

Συμβατικά συνθετικά ανοσοτροποποιητικά φάρμακα (csDMARDs) στη θεραπεία της PA

Χρήστος Κουτσιανάς

Ρευματολόγος – Ειδικός παθολόγος




Ακαδημαϊκός υπότροφος, Μονάδα Κλινικής Ανοσολογίας - Ρευματολογίας, Β Πανεπιστημιακή Παθολογική Κλινική και Ομώνυμο Εργαστήριο, ΓΝΑ «»Ιπποκράτειο»


> Honorary Consultant, Research & Development Department The Dudley Group NHS Foundation Trust



Introduction: RA natural history




Introduction: RA natural history




Introduction: RA evolution




Introduction: RA evolution




▲ Figure 15–3. Progressive destruction of a metacarpophalangeal joint by rheumatoid arthritis. Shown are sequential radiographs of the same second metacarpophalangeal joint. A: The joint is normal 1 year prior to the development of rheumatoid arthritis. B: Six months following the onset of rheumatoid arthritis, there is a bony erosion adjacent to the joint and joint-space narrowing. C: After 3 years of disease, diffuse loss of articular cartilage has led to marked joint-space narrowing.




Introduction: why DMARDs?



Introduction: why DMARDs?




Introduction: Treatment paradigm shift in RA




"Go Low, Go Slow"

"Treat to target"




Antimalarials

 Chloroquine 250mg/day (<3.0 mg/kg IBW) (engineered in Germany after WWI, as alternative to quinine)



• Quinacrine 100-200mg/day





Froms 184. Ataleine publicity campaign, 263d Station Hospital, March 1944.


Hydroxychloroquine

- 4-aminoquinolone derivative from the bark of the Peruvian cinchona tree
- > 1955: Approved for medical use in the US

- Least toxic of all the DMARDs
- Particularly effective in:
 - mild arthritis
 - early treatment
 - add-on therapy



- No effect of food on absorption (100%)
- High concentration in melatonin-rich cells (skin, retina)
- 50% renal excretion
- Half-life 40-50 days
- Steady state levels after 3 6 months
- No need for monitoring bloods



Hydroxychloroquine: mechanism of action


Precise MoA not known

Weak base

Accumulate in cytoplasmic vesicles (increase pH)

Theory #1: increase in pH has several immunomodulatory effects

- stabilization of lysosomal membranes
- attenuation of antigen processing
- inhibition of cell-mediated toxicity



Hydroxychloroquine: mechanism of action

Precise MoA not known

Weak base


Accumulate in cytoplasmic vesicles (increase pH)

Theory #1: increase in pH has several immunomodulatory effects

- stabilization of lysosomal membranes
- attenuation of antigen processing
- inhibition of cell-mediated toxicity

Theory #2: inhibition of intracellular Toll-like receptors (esp TLR9)

- inhibitory effect on IL-1, IL-6 and IFN γ



Hydroxychloroquine: other effects

- Photoprotective
- □ Anti-thrombotic effect Inhibit PLT adhesion and aggregation
- □ Favorable lipid effects
- Decrease plasma glucose levels (inhibition of insulin degradation)



Hydroxychloroquine: side effects

- Gastrointestinal (<10%): anorexia, nausea, vomiting, diarrhea, abdominal cramping
- **Dermatological (<5%):** pruritic rash – relatively common, can lead to d/c photosensitivity, alopecia, depigmentation of hair skin pigmentation with prolonged Rx
- Neuromuscular (<1%):</p>

Headache, insomnia, nightmares, and irritability (usually improve with treatment) Tinnitus, deafness Neuromyotoxicity (high CK, weakness) + peripheral neuropathy (rare)

Cardiovascular (<1%): Conduction disturbances, cardiomyopathy





Hydroxychloroquine: fertility, pregnancy & lactation

SAFE

✓ Not teratogenic

✓ Safe to use throughout pregnancy
✓ Favourable pregnancy outcomes, esp in SLE
✓ Compatible with breastfeeding



Hydroxychloroquine: ocular toxicity


Bilateral **"bull's eye" maculopathy**, with **retinal pigment epithelial (RPE) cell depigmentation** in the central macula and sparing of a small foveal island


Increased risk for toxicity among patients receiving doses > 5 mg/kg/day of actual body weight.

Depends on duration of use

- < 5 years: close to 0%
- < 10 years: 2%
- > 20 years: 20%

Mechanism: ? Genetic component ?changes in metabolism





Hydroxychloroquine: ocular toxicity


Risk factors:

- Daily HCQ dose
- Duration of therapy
- Renal failure
- Tamoxifen
- Underlying retinal or macular disease / pre-existing retinal abnormalities



Hydroxychloroquine: ocular toxicity - monitoring


- AAO: baseline eye exam within 1 year Visual acuity, corneal / retinal exam / colour-vision testing OCT at baseline **not** recommended
 - Routine **annual** eye screening for the first 5 years
 - Then, more detailed tests with OCT
- **RCO:** detailed exams after 5 years



Methotrexate


Methotrexate

- First used for malignant diseases
- Aminopterin first used for RA in 1951
- Anchor drug in RA for the last several decades
- Structurally similar to folic acid






Methotrexate: mechanism of action



Adenosine A2A receptors are expressed on T cells, natural killer cells, monocytes, macrophages, and neutrophils

Inflammation dampened by several mechanisms:

- T-cell suppression
- inhibition of the neutrophil oxidative burst
- suppression of NF-кВ



Methotrexate: pharmacology

- Available in oral and subcutaneous form
- Oral: doses > 15mg QWK may not be absorbed by 30%
- Split dose improve bioavailability
- Not reduced by food intake

- Serum half-life 6-8h
- Renal clearance










Table 2. Summary of adverse events during the study (safety analysis se	Table 2.	Summary	of adverse	events during	the study	(safety	analysis a	set)*
---	----------	---------	------------	---------------	-----------	---------	------------	-----	----

	No. (%) of patients receiving SC MTX (n = 102)	No. (%) of patients receiving oral MTX (n - 188)
	(n = 193)	(n = 188)
Adverse events		
Any adverse event	128 (66)	116 (62)
At least a moderate adverse event	79 (41)	77 (41)
Adverse event possibly related to study drug	102 (53)	90 (48)
Serious adverse event	11 (5.7)	8 (4.3)
Adverse event leading to withdrawal	18 (9.3)	8 (4.3)
At least moderate adverse events reported at a $\geq 3\%$ incidence		
Gastrointestinal		
Abdominal pain	17 (8.8)	20 (10.6)
Diarrhea	5 (2.6)	13 (6.9)
Dyspepsia	13 (6.7)	11 (5.9)
Loss of appetite	14 (7.3)	6 (3.2)
Nausea	32 (16.6)	23 (12.2)
Stomatitis	6 (3.1)	7 (3.7)
Vomiting	7 (3.6)	6 (3.2)
Increased alanine aminotransferase	3 (1.6)	8 (4.3)
Bronchitis	4 (2.1)	/ (3./)
Headache	4 (2.1)	8 (4.3)
Nasopharyngitis	9 (4.7)	10 (5.3)

* Methotrexate (MTX) was administered subcutaneously (SC) or orally.


Methotrexate: dosage

- Starting dose 10-15mg/wk
- Dose optimization according to tolerability & efficacy within 3 months
- Usually up to 25mg/wk
- <u>Concomitant administration of folic acid</u>: decreases several side effects (GI upset, hair thinning, stomatitis, fatigue, haematologic toxicity) Usually 5mg QWK (US: 1mg/day)
- Extra caution in geriatric population and reduced CrCl

Methotrexate: efficacy

Efficacy of methotrexate as monotherapy in studies of biologics

	TEMPO*	PREMIER [†]	ASPIRE [‡]	COMET⁵	AMBITION	Abatacept study ¹
ACR20 (%)	75	63	54	67	52	Not reported
ACR50 (%)	43	46	32	49	34	43
ACR70 (%)	19	28	21	28	28	27
DAS remission (%)	13	21	15	28	12	23



Strik et al. Aliment Pharmacol Ther. 2017 Apr;45(8):1128-1134

Methotrexate: side effects


Gastrointestinal:

anorexia, dyspepsia, nausea, vomiting (20-70%) folic acid supplementation may be of help

Hepatotoxicity:

elevated aminotransferases frequently risk of significant hepatotoxicity rather low no significant risk of liver fibrosis with the use of the drug

 Mucocutaneous: stomatitis, usually minor aphthous ulcerations



Haematologic:

Bone marrow toxicity (dose dependent) < 1-2% responds to folic acid supplementation — in severe case, leucovorin iv + GM-CSF Risk factors: renal failure, hypoalbuminaemia, dosing errors, concomitant use of other drugs (e.g. probenecid, SMX/TMP)

✓ **Pulmonary**:

- acute interstitial pneumonitis: rare, hypersensitivity reaction
- pleuritis & pleural effusions
- interstitial fibrosis: ?does it really exist
- pulmonary nodules
- non-cardiogenic pulmonary oedema

✓ Other:

"methotrexate flu" nodulosis



Methotrexate: treatment considerations

Perioperative management:
2022 ACR/AAKHS guidelines¹ – no need to stop for arthroplasty surgery

✓ Vaccination:

discontinuation 1-2 weeks after the flu vaccine had increased rated of immunogenicity²



^{1.} Goodman et al. Arthritis Care Res 2022 2. Park et alArthritis Rheumatol 2022 Aug 05

Methotrexate: fertility, pregnancy & lactation

Teratogenic

"aminopterin syndrome": craniofacial, limb & CNS abnormalities

WOMEN:

✓ Discontinue at least 3 mo prior to conception efforts

- ✓ Folic acid supplementation
- ✓ Contraindicated during lactation

<u>MEN</u>:


Although the drug label suggests d/c of MTX before attempting pregnancy, data show no evidence for mutagenesis or teratogenicity – ACR guidelines: conditionally continue



Leflunomide


Leflunomide


- Isoxazole derivative
- Converted to active metabolite, teriflunomide
- Immunomodulatory effect
- Orally administered




Leflunomide: mechanism of action


- Inhibitor of DHODH
- Stops pyrimidine synthesis
 - ✓ Blocks proliferation of lymphocytes
 - Inhibits NF-Kβ activation & gene expression
 - ✓ Suppresses IL-17 and IL-1 pathways
 - ✓ Inhibits chemotaxia of neutrophils





Leflunomide: efficacy





Leflunomide: side effects

 Cardiovascular: Arterial hypertension.

✓ Gastrointestinal:

anorexia, dyspepsia, diarrhea, abdominal pain abnormal aminotransferases


Cutaneous:

Skin reactions (~10%). Most between 2nd – 5th month Alopecia

✓ Infection

✓ Neurologic:

headache, dizziness, parasthesia (usually mild)



LEF WASH OUT 1. Cholestyramine 8g TDS for 11 days 2. Activated charcoal 50gr QDS for 11 days

Leflunomide: treatment considerations

Perioperative management:
2022 ACR/AAKHS guidelines¹ – no need to stop for arthroplasty surgery

Vaccination:
no need to discontinued treatment



Leflunomide: fertility, pregnancy & lactation

Teratogenic

WOMEN:

- ✓ Discontinue at least 24 mo prior to conception efforts
- ✓ Cholestyramine wash out
- ✓ Measurement of drug levels?

<u>MEN</u>:

ACR 2020 guidelines – conditionally continue



Sulfasalazine

Sulfasalazine

- 1938: produced in the lab by Dr Svartz
- Drug for RA in mid 70s
- Not very commonly used today, due to lack of convincing efficacy
- Mainly used in combined regimens
- Maybe better in SpA and peripheral arthritis/enthesitis

• Dosage 2g/d (up to 3g/day)



Sulfasalazine


Metabolised in the liver and gut into:

- sulfapyridine (absorbed systematically)
- 5-ASA (mainly active in the bowel)

Excreted unchanged in urine Elimination half-life ~5 hrs

MECHANISM OF ACTION

- Inhibits pro-inflammatory effects of the arachidonic acid cascade
- inhibits neutrophil activation by decreasing the flux of second messengers involved in intra-cellular signalling
- Inhibits enzymes of phosphorylation activity like MTX does



Sulfasalazine: side effects

- Gastrointestinal: anorexia, dyspepsia, nausea, diarhhea withdrawal rate 25%
- ✓ Cutaneous: pruritic rash
 DRESS syndrome
- ✓ Haematologic:

Leukopenia<3% usually transient rarely severe agranulocytosis G6PD deficiency →haemolsis decrease in Igs, megaloblastic anaemia

✓ other:

hepatotoxicity (usually mild), eosinophilic pneumonia, and anaphylactic reactions.



Sulfasalazine: treatment considerations

Perioperative management:
2022 ACR/AAKHS guidelines¹ – no need to stop for arthroplasty surgery

Vaccination:
discontinuation 1-2 weeks after the flu vaccine²



1. Goodman et al. Arthritis Care Res 2022 2. ACR guidelines for COVID vaccination 2022

Sulfasalazine: fertility, pregnancy & lactation

WOMEN:

✓ Continue with added folic acid supplementation✓ Can be used throughout pregnancy and lactation

MEN:

Reversible oligospermia



Sammaritano et al Arthritis Rheumatol 2020

Honourable mentions...

Honourable mentions

• Gold salts:

injectable and per os (auranofin). MoA not understood - ?reduce oxidative stress

transient symptoms of flushing, sweating, dizziness, nausea, hypotension, and malaise that occur within minutes of drug administration

Cutaneous reactions (chrysiasis)

• Cyclosporin:

calcineurin inhibitor – regulates gene coding for IL2 (T-cell inhibition) drug interactions dose related decrease in eGFR, arterial hypertension hirsuitism, gingival hyperplasia

• Tetracyclines:

antibiotics with modest clinical benefit in RA Hyperpigmentation and drug induced lupus











Thank you for your attention



rheumhippo@gmail.com

ckoutsianas@gmail.com